Abstract
CADTH recommends that Paxlovid be reimbursed by public drug plans for the treatment of mild to moderate COVID-19 in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death, if certain conditions are met. Paxlovid should only be covered to treat patients who have severe or moderate immunosuppression as described in Table 1. Treatment should be initiated as soon as possible within 5 days of symptom onset. Paxlovid should only be reimbursed if the cost is reduced.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
